Pyridine Salt and Crystal Forms for Selective TYK2 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TYK2 inhibitors, such as orthosteric and allosteric inhibitors, face challenges in achieving selective inhibition of TYK2 while maintaining efficacy and safety for treating inflammatory and autoimmune diseases, with limited clinical data on allosteric inhibitors like BMS-986165 and FTP-637.
Innovation Solution
A novel crystal form of a multi-substituted pyridine compound, characterized by specific X-ray powder diffraction peaks, is developed to enhance the selectivity and stability of TYK2 inhibition, potentially improving treatment outcomes for conditions like psoriasis, Crohn's disease, and systemic lupus erythematosus.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If orthosteric inhibitors targeting the kinase domain (JH1) are used to inhibit TYK2, then kinase activity is blocked, but selectivity against other JAK family members is reduced
Solution Approach 1:
The patent targets the pseudokinase domain (JH2) of TYK2 rather than the conserved kinase domain (JH1), exploiting the unique structural characteristics of TYK2's JH2 domain to achieve selective inhibition. The compound binds specifically to TYK2's JH2 domain, which has distinct structural features compared to other JAK family members, thereby achieving local specificity that spares other kinases.
Solution Approach 2:
Instead of inhibiting the active kinase domain (JH1) as done by conventional orthosteric inhibitors, the patent inverts the approach by targeting the pseudokinase domain (JH2), which is normally considered inactive. This inverted targeting strategy enables selective inhibition of TYK2 while preserving activity in other JAK family members.
2Object-affected harmful factors
If allosteric inhibitors targeting the pseudokinase domain (JH2) are used to achieve selective TYK2 inhibition, then selectivity is improved, but clinical data and proven efficacy are limited
Solution Approach 1:
The patent optimizes the chemical structure parameters of the pyridine compound, specifically adjusting substituents at positions R1-R6 to fine-tune binding affinity and pharmacokinetic properties. This structural optimization enhances both selectivity and clinical potential while maintaining allosteric inhibition mechanism.
Solution Approach 2:
The compound incorporates a multifaceted molecular structure combining a pyridine core with specific substituent groups that collectively provide both selective binding to TYK2's JH2 domain and favorable pharmacokinetic properties, effectively integrating multiple functional requirements into a single molecular entity.
3Stability of the object's composition
If a new crystal form of the pyridine compound is developed to enhance stability, then pharmacokinetic properties are improved, but manufacturing complexity increases
Solution Approach 1:
The patent performs preliminary crystal form selection and optimization during the drug development process, identifying and characterizing the most stable crystal form (Form A) before scale-up manufacturing. This advance characterization prevents manufacturing issues later and simplifies the production process by establishing clear crystal form specifications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystal form of the pyridine compound exhibits excellent pharmacokinetic properties and stability, making it suitable for drug development and providing a therapeutic option with enhanced selectivity and safety for TYK2 inhibition.
Implementation Method 1
small molecule ligands that bind to JH2 stabilize the autoinhibitory interaction between the JH2 domain and the JH1 active site
Implementation Method 2
the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 17.56±0.20°, 24.36±0.20°, 25.69±0.20°, and 27.37±0.20°
Data Source
Figure 1~2
Figure 3
AI summary
Disclosed in the present invention are a salt form and a crystal form of a pyridine multi-substituted compound and a preparation method therefor. Specifically disclosed is the use of a crystal form of a compound of formula (I) and a preparation method therefor in the preparation of a drug for treating related diseases.